CLINICAL TRIALS PROFILE FOR METHOCARBAMOL
✉ Email this page to a colleague
All Clinical Trials for methocarbamol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02432456 ↗ | Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients | Completed | Medical College of Wisconsin | Phase 4 | 2015-09-01 | This study will evaluate the effectiveness of ketamine infusions in the management of acute pain resulting from broken ribs suffered following a blunt trauma. Half of patients will receive the institutional standard of care and a placebo infusion (no active medication). The other half of patients will receive the institutional standard of care and a ketamine infusion. All subjects and staff will be blinded as to whether they are receiving placebo or ketamine. |
| NCT02642874 ↗ | Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients | Unknown status | Tanta University | Phase 3 | 2017-04-01 | Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe and effective dosages. |
| NCT02665286 ↗ | Orphenadrine and Methocarbamol for LBP | Completed | Montefiore Medical Center | Phase 4 | 2016-03-01 | Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone |
| NCT02831569 ↗ | Japanese IP-TN Trial | Completed | SSP Co., Ltd. | Phase 3 | 2016-07-27 | This is an open-label, single-group, multi-centre trial to confirm the safety and efficacy of loxoprofen sodium/methocarbamol ( IP-TN) when administered orally for 2 weeks to patients with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome associated with muscle strain. More than 90 patients will be screened to enroll approximately 80 patients in the trial. After giving written informed consent, patients will be enrolled in the trial. Patients who are considered eligible for the trial by the Investigator after consent and complete the trial procedures and assessments at Visit 1 will receive the trial medication and enter the open-label treatment period of 2 weeks. Patients who complete the open-label treatment period will enter the follow-up period of 1 week and complete the trial after confirmation at the last visit (or phone interview). |
| NCT02831569 ↗ | Japanese IP-TN Trial | Completed | Boehringer Ingelheim | Phase 3 | 2016-07-27 | This is an open-label, single-group, multi-centre trial to confirm the safety and efficacy of loxoprofen sodium/methocarbamol ( IP-TN) when administered orally for 2 weeks to patients with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome associated with muscle strain. More than 90 patients will be screened to enroll approximately 80 patients in the trial. After giving written informed consent, patients will be enrolled in the trial. Patients who are considered eligible for the trial by the Investigator after consent and complete the trial procedures and assessments at Visit 1 will receive the trial medication and enter the open-label treatment period of 2 weeks. Patients who complete the open-label treatment period will enter the follow-up period of 1 week and complete the trial after confirmation at the last visit (or phone interview). |
| NCT04464512 ↗ | Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population | Recruiting | West Virginia Clinical and Translational Science Institute | Phase 4 | 2020-01-10 | Suboxone treated patients present a unique challenge to providers during the perioperative period in terms of pain control. If the patient is taken off their prescribed suboxone 48 hours prior to the procedure, the opioid pain medication will function but the patient is exposed to the very medications originally responsible for their substance addiction. The discontinuation of suboxone can potentially lead to opioid addiction relapse in this situation (Anderson et al., 2017). If the patient remains on their suboxone, opioid pain medications can be ineffective or require very large dosages to control pain but the patient's risk of relapse may be lower (Anderson et al., 2017). Classic opioid pain medications prescribed by providers for post-operative pain control such as hydromorphone, morphine and fentanyl have lower affinity for the Mu 1 and 2 receptors when compared to buprenorphine. These medications are less effective or ineffective when given to a patient treated with Suboxone due to their inability to bind to the Mu receptor in the presence of buprenorphine. The only clinically used full agonist opioid with stronger affinity for the MU 1 and 2 receptors is sufentanil. In theory, sufentanil would be able to displace buprenorphine from the receptor and stimulate the receptor as a full agonist leading to predictable pain control. Through the Kappa receptor antagonism, buprenorphine may improve the treatment of opioid-induced hyperalgesia (Koppert W et al., 2005). Additional benefits may include buprenorphine's Kappa receptor antagonism may help in treating forms of depression and depression (Lalanne et al., 2014). At our institution, orthopedic trauma patients have a high incidence of suboxone use and make an ideal study population as they are often otherwise healthy. Our study compares opioid consumption in the perioperative period in patients taking suboxone on presentation to the operating room. The patients will randomized to receive conventional opioid based regimen versus buprenorphine and sufentanil based opioid regimen. The goal of the study is to determine if the combination of buprenorphine and sufentanil based pain control is superior to classic opioid treatment strategies in patients taking suboxone while presenting for orthopedic trauma surgery. |
| NCT04464512 ↗ | Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population | Recruiting | West Virginia University | Phase 4 | 2020-01-10 | Suboxone treated patients present a unique challenge to providers during the perioperative period in terms of pain control. If the patient is taken off their prescribed suboxone 48 hours prior to the procedure, the opioid pain medication will function but the patient is exposed to the very medications originally responsible for their substance addiction. The discontinuation of suboxone can potentially lead to opioid addiction relapse in this situation (Anderson et al., 2017). If the patient remains on their suboxone, opioid pain medications can be ineffective or require very large dosages to control pain but the patient's risk of relapse may be lower (Anderson et al., 2017). Classic opioid pain medications prescribed by providers for post-operative pain control such as hydromorphone, morphine and fentanyl have lower affinity for the Mu 1 and 2 receptors when compared to buprenorphine. These medications are less effective or ineffective when given to a patient treated with Suboxone due to their inability to bind to the Mu receptor in the presence of buprenorphine. The only clinically used full agonist opioid with stronger affinity for the MU 1 and 2 receptors is sufentanil. In theory, sufentanil would be able to displace buprenorphine from the receptor and stimulate the receptor as a full agonist leading to predictable pain control. Through the Kappa receptor antagonism, buprenorphine may improve the treatment of opioid-induced hyperalgesia (Koppert W et al., 2005). Additional benefits may include buprenorphine's Kappa receptor antagonism may help in treating forms of depression and depression (Lalanne et al., 2014). At our institution, orthopedic trauma patients have a high incidence of suboxone use and make an ideal study population as they are often otherwise healthy. Our study compares opioid consumption in the perioperative period in patients taking suboxone on presentation to the operating room. The patients will randomized to receive conventional opioid based regimen versus buprenorphine and sufentanil based opioid regimen. The goal of the study is to determine if the combination of buprenorphine and sufentanil based pain control is superior to classic opioid treatment strategies in patients taking suboxone while presenting for orthopedic trauma surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for methocarbamol
Condition Name
Clinical Trial Locations for methocarbamol
Trials by Country
Clinical Trial Progress for methocarbamol
Clinical Trial Phase
Clinical Trial Sponsors for methocarbamol
Sponsor Name
